Fexofénadine Winthrop may be available in the countries listed below.
Fexofenadine hydrochloride (a derivative of Fexofenadine) is reported as an ingredient of Fexofénadine Winthrop in the following countries:
International Drug Name Search
Velacin may be available in the countries listed below.
Doxycycline is reported as an ingredient of Velacin in the following countries:
International Drug Name Search
Nifestad may be available in the countries listed below.
Nifedipine is reported as an ingredient of Nifestad in the following countries:
International Drug Name Search
Rec.INN
0141388-76-3
C19-H21-Cl-F-N3-O3
393
Chemotherapeutic
Antibacterial: Gyrase inhibitor
(+)-7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4oxo-1,4-dihydroquinoline-3-carboxylic acid
7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (WHO)
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Each Dallergy PE Caplet (capsule shaped caplet) contains:
Chlorpheniramine Maleate . . . . . . . . . . . 8 mg
Methscopolamine Nitrate . . . . . . . . . . . 2.5 mg
Phenylephrine Hydrochloride . . . . . . . . 20 mg
in a specially prepared base to provide a prolonged therapeutic effect.
Chlorpheniramine Maleate is an antihistamine having the chemical name 2-pyridinepropanamine, γ-(4 chlorophenyl)- N,N-dimethyl, (Z)-2- butenedioate (1:1), having the following structural formula:
C16H19ClN2 • C4H4O4 M.W. 390.86
Methscopolamine Nitrate is an anticholinergic having the chemical name 3-Oxa-9-azoniatricyclo [3.3.1.02,4]nonane, 7-(3-hydroxy-1-oxo-2-phenylpropoxy)- 9, 9- dimethyl-, nitrate, [7(S)-(1α, 2β, 4β, 5α, 7β)]-, having the following structural formula:
C18H24NO4• NO3 M.W. 380.4
Phenylephrine Hydrochloride is a decongestant having the chemical name Benzenemethanol, 3-hydroxy-α- [(methylamino)methyl]-, hydrochloride (R)-, having the following structural formula:
C9H13NO2 • HCl M.W. 203.67[/IC]
Dallergy PE Caplets contain ingredients of the following therapeutic classes: antihistamine, antisecretory agent, and nasal decongestant.
Inactive ingredients include: calcium phosphate, magnesium stearate, methylcellulose, povidone, and stearic acid.
Chlorpheniramine Maleate is an alkylamine type antihistamine. This group of antihistamines is among the most active histamine antagonists and is generally effective in relatively low doses. The drugs are not so prone to produce drowsiness and are among the most suitable agents for daytime use; but a significant proportion of patients do experience this effect.
Methscopolamine Nitrate is a quaternary ammonium derivative of scopolamine, which possesses the peripheral actions of the belladonna alkaloids, but does not exhibit the central actions because of its lack of ability to cross the blood-brain barrier. In this formulation, it is used because of its antisecretory effects on the respiratory system.
Phenylephrine Hydrochloride is a sympathomimetic amine which acts predominantly on alpha receptors and has little action on beta receptors. It, therefore, functions as an oral nasal decongestant with minimal CNS stimulation.
This product is indicated for the relief of upper respiratory symptoms due to seasonal and perennial allergic and non-allergic rhinitis, such as: nasal congestion, sinusitis, sneezing, lacrimation, vasomotor rhinitis, post-nasal drip, and hay fever.
Dallergy PE Caplets are contraindicated in patients with hypersensitivity to any of the ingredients. It is also contraindicated in patients with severe hypertension, severe coronary artery disease, patients on monoamine oxidase inhibitor (MAOI) therapy, patients with narrow angle glaucoma, urinary retention, peptic ulcer, and during an asthmatic attack.
Considerable caution should be exercised in patients with hypertension, diabetes mellitus, ischemic heart disease, hyperthyroidism, increased intraocular pressure, and prostatic hypertrophy. The elderly (60 years or older) are more likely to exhibit adverse reactions. Antihistamines may cause excitability, especially in children. At dosages higher than the recommended dose, nervousness, dizziness, or sleeplessness may occur. Do not exceed recommended dosage.
Caution should be exercised in patients with high blood pressure, heart disease, diabetes, or thyroid disease. The antihistamine in this product may exhibit additive effects with other CNS depressants, including alcohol.
Antihistamines may cause drowsiness, and ambulatory patients who operate machinery or motor vehicles should be cautioned accordingly.
MAOIs and beta adrenergic blockers increase the effects of sympathomimetics. Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids. Concomitant use of antihistamines with alcohol and other CNS depressants may have an additive effect.
Pregnancy Category C: Animal reproduction studies have not been conducted with Dallergy PE Caplets. It is also not known whether Dallergy PE Caplets can cause fetal harm when administered to a pregnant woman, or can affect reproduction capacity. Dallergy PE Caplets should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dallergy PE Caplets are administered to a nursing mother.
Safety and effectiveness in pediatric patients under 6 years of age have not been established. Use of antihistamines is not recommended in newborn or premature infants because this age group has an increased susceptibility to anticholinergic side effects, such as CNS excitation, and an increased tendency toward convulsion. In infants and children, overdosage may cause hallucinations, convulsions, and death. A paradoxical reaction characterized by hyperexcitability may occur in older children taking antihistamines. Use is not recommended for children under six (6) years of age. Infants and young children are especially susceptible to the toxic effects of anticholinergics. Close supervision is recommended for infants and children with spastic paralysis or brain damage since an increased response to anticholinergics has been reported in these patients, and dosage adjustments are often required.
When anticholinergics are given to children where the environmental temperature is high, there is a risk of a rapid increase in body temperature because of the suppression of sweat gland activity. A paradoxical reaction characterized by hyperexcitability may occur in children taking large doses of anticholinergics. Appropriate studies with phenylephrine have not been performed in the pediatric population; however, no pediatric- specific problems have been documented to date.
Confusion, hallucinations, seizures, and CNS depression may be more likely to occur in geriatric patients taking sympathomimetic amines. Geriatric patients also may be more sensitive to the effects, especially the vasopressor effects, of sympathomimetic amines. Confusion, dizziness, sedation, hypotension, hyperexcitability, and anticholinergic side effects, such as dryness of mouth and urinary retention (especially in males), may be more likely to occur in geriatric patients taking antihistamines. Geriatric patients may respond to usual doses of anticholinergics with excitement, agitation, drowsiness, or confusion. Geriatric patients are especially susceptible to the anticholinergic side effects, such as constipation, dryness of mouth, and urinary retention (especially in males). If these side effects occur and continue or are severe, medication should probably be discontinued. Caution is also recommended when anticholinergics are given to geriatric patients, because of the danger of precipitating undiagnosed glaucoma. Memory may become severely impaired in geriatric patients, especially those who already have memory problems, with the continued use of anticholinergics, since these drugs block the action of acetylcholine, which is responsible for many functions of the brain, including memory function.
Adverse reactions include drowsiness, lassitude, nausea, giddiness, dryness of mouth, blurred vision, cardiac palpitations, flushing, increased irritability or excitement (especially in children).
In all cases of suspected overdose, immediately call your regional poison control center, and/or contact a physician immediately. The stomach should be emptied promptly by lavage or by induction of emesis with Syrup of Ipecac. The installation of activated charcoal into the stomach also should be considered. The treatment of overdose is essentially symptomatic and supportive. If respiratory depression is present, treat promptly with oxygen and/or mechanical support of ventilation. If convulsions or marked CNS excitement occurs, only short-acting benzodiazepine type drugs should be used.
Dallergy PE Caplets: Adults and children 12 years of age and older: 1 caplet every 12 hours, not to exceed 2 caplets a day. Children 6 to under 12 years: As prescribed by a physician.
Not recommended for children under 6 years of age.
Caplets should not be crushed or chewed prior to swallowing.
Dallergy PE Caplets are white, capsule shaped caplets with “LAS 154” debossed on one side. The opposite side is plain. Available in bottles of 100 caplets (NDC 68134-154-01).
Store at 20°-25°C (68°-77°F); excursions permitted to 15°- 30°C (59°-86°F). See USP Controlled Room Temperature.
Dispense in a tight, light-resistant container as defined in the USP/NF with a child resistant closure.
KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN. IN CASE OF ACCIDENTAL OVERDOSE, SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.
Rx Only
Manufactured for:
Palmetto Pharmaceuticals, Inc.
Greenville, SC 29615
500396 Rev. 04/2010
Figure 1 Container Label
| DALLERGY PE chlorpheniramine maleate / methscopolamine nitrate / phenylephrine hcl tablet, extended release | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| Unapproved drug other | 07/08/2010 | ||
| Labeler - Palmetto Pharmaceuticals, Inc. (963291864) |
| Registrant - Palmetto Pharmaceuticals, Inc. (963291864) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Sovereign Pharmaceuticals, LLC | 623168267 | MANUFACTURE | |
Zo-20 may be available in the countries listed below.
Simvastatin is reported as an ingredient of Zo-20 in the following countries:
International Drug Name Search
Diclofenaco Lepori may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclofenaco Lepori in the following countries:
International Drug Name Search
Algibaume may be available in the countries listed below.
Diethylamine Salicylate is reported as an ingredient of Algibaume in the following countries:
International Drug Name Search
